Revisado por Isabelle Baião de Mello Neto (CRF-MG 24309)Dizeres Legais do Sygen
M.S - 1.0341.0003.006-1
Farmacêutico responsável:
Dawerson Rodrigues
CRF-SP 12370
TRB Pharma Indústria Química e Farmacêutica Ltda
Rua Hildebrando Siqueira, 149 - Americanópolis
São Paulo – SP – CEP 04334-150
CNPJ: 61.455.192/0002-04
Indústria Brasileira
SAC
0800-105588
Venda sob prescrição médica.
Referências Bibliográficas
Alter M. GM1 ganglioside for acute ischemic stroke. Trial design issues. Ann N Y Acad Sci, v. 845, p. 391-401, 1998.
Conceicao I, Carvalho M, Alves M, Parreira E, Martins A, Ferro J and Sales-Luis ML. [Relationship between parenteral gangliosides administration and the Guillain-Barre syndrome]. Rev Neurol, v. 28, p. 1033-1035, 1999.
Govoni V, Granieri E, Tola MR, Paolino E, Casetta I, Fainardi E and Monetti VC. Exogenous gangliosides and Guillain-Barre syndrome. An observational study in the local health district of Ferrara, Italy. Brain, v. 120, p. 1123-1130, 1997.
Govoni, V.; Granieri, E.; Mamconi, M.; Capone, J.; Casetta, I. Is there a decrease in Guillain-Barré syndrome incidence after bovine ganglioside withdrawal in Italy? A population-based study in the Local Health District of Ferrara, Italy. Journal of the Neurological Sciences, v. 216(1), p. 99-103, 2003.